Paid Clinical Trials Springfield

Discover 48 paid clinical trials in Springfield, Illinois. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 48

BR-AMNon-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM

Recruiting

Sponsor:

BioStem Technologies

Location:

Springfield IL, Detroit MI, Guntersville AL, Chapel Hill NCshow 10 more

Code:

NCT06565156

Conditions

Non-infected Diabetic Foot Ulcer

Diabetic Foot

Diabetic Wound

Diabetic Foot Ulcer

Non-ischemic Diabetic Foot Ulcer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BR-AM

Standard Care

Dipraglurant with LevodopaDipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Recruiting

PHASE2

PHASE3

Sponsor:

Addex Pharma S.A.

Location:

Springfield IL, Chicago IL, Indianapolis IN, Madison WIshow 37 more

Code:

NCT04857359

Conditions

Parkinson Disease

Dyskinesia, Drug-Induced

Dyskinesias

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Dipraglurant

Placebo

tDCSPivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

Recruiting

Sponsor:

Neuroelectrics Corporation

Location:

Springfield IL, Saint Louis MO, Nashville TN, Rochester MNshow 12 more

Code:

NCT04770337

Conditions

Refractory Epilepsy

Focal Seizure

Seizures, Focal

Seizures

Epilepsy in Children

Eligibility Criteria

Sex: All

Age: 9+

Healthy Volunteers: Not accepted

Interventions

STARSTIM device

Sham Device

XEN1101A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Recruiting

PHASE3

Sponsor:

Xenon Pharmaceuticals Inc.

Location:

Springfield IL, Nashville TN, Columbus OH, Detroit MIshow 5 more

Code:

NCT05716100

Conditions

Focal Onset Seizures

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

XEN1101

Placebo

Tissue Repair GelTissue Repair Gel in Venous Leg Ulcers (US)

Recruiting

PHASE3

Sponsor:

TR Therapeutics

Location:

Springfield IL, Grove City OH, Tulsa OK, Mentor OHshow 14 more

Code:

NCT06707090

Conditions

Venous Leg Ulcer

Venous Ulcer

Venous Stasis Ulcer

Venous Stasis

Wound Heal

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TR987 0.1% gel + Standard of Care

Standard of care

Observational StudyCollection of Samples USOPTIVAL Study

Recruiting

Sponsor:

Universal Diagnostics

Location:

Springfield IL, Union City TN, Uniontown PA, Roanoke VAshow 10 more

Code:

NCT04792684

Conditions

Colorectal Cancer (CRC)

Advanced Adenomas (AA)

Eligibility Criteria

Sex: All

Age: 45 - 70+

Healthy Volunteers: Accepted

Interventions

Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel

Esprit BTKEsprit BTK Post-Approval Study

Recruiting

Sponsor:

Abbott Medical Devices

Location:

Springfield IL, Chicago IL, Indianapolis IN, Cincinnati OHshow 28 more

Code:

NCT06656364

Conditions

Chronic Limb-Threatening Ischemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Esprit BTK System

Curvafix®Curvafix® Intramedullary System for Fixation of Pelvic and Acetabular Fractures, A Post Market Evaluation

Recruiting

Sponsor:

CurvaFix, Inc.

Location:

Springfield IL, Columbia MO, Columbus OH, San Antonio TX

Code:

NCT05606042

Conditions

Pelvic Ring Fracture

Acetabular Fracture

Pelvic Fracture

Pelvic Fracture Acetabulum

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

IM Implant

Aortic Valve-in-ValvePARTNER 3 Trial - Aortic Valve-in-Valve

Recruiting

Sponsor:

Edwards Lifesciences

Location:

Springfield IL, Saint Louis MO, Chicago IL, Evanston ILshow 43 more

Code:

NCT03003299

Conditions

Aortic Stenosis

Aortic Stenosis, Severe

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Edwards SAPIEN 3/SAPIEN 3 Ultra THV

Enasidenib & Cedazuridine-DecitabineTesting the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Springfield IL, Decatur IL, Pekin IL, Canton ILshow 25 more

Code:

NCT06577441

Conditions

Myelodysplastic Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine and Cedazuridine

Enasidenib